ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections

Oct 16, 2017

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia...

ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients

Jul 25, 2017

Labège, France, 25 July 2017. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest...

ANTABIO receives €4 Million to develop new drugs to treat chronic infections in Cystic Fibrosis patients

May 12, 2015

Antabio SAS, a leading biopharmaceutical company in the field of antibacterial drug discovery, announced today that it has received a Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of chronic Pseudomonas infections...

Antabio awarded EUR 1 million funding from Bpifrance to support the discovery of New Gram-Negative Anti-Infective Agents

Apr 9, 2015

Antabio SAS, a French antibacterial drug discovery company, and Bpifrance, announce that Antabio will receive EUR 1 million in funding to support its Antibiotic Adjuvant Factory (“The Factory”) dedicated to the discovery and development of new antibacterial...

Antabio awardee of the “Concours Mondial de l’Innovation 2030” Worldwide Innovation Challenge

Jul 23, 2014

Antabio annonce que son projet de découverte de nouveaux traitements pour les patients atteints de mucoviscidose a été primé par le Concours Mondial de l’Innovation 2030.Labège, France, 23 juillet 2014. Antabio, société biopharmaceutique française spécialisée dans la...

Argenta and Antabio Announce Achievement of Milestone in their Anti-bacterial Drug Discovery Collaboration

Mar 10, 2014

Harlow, UK and Labège, France, 10th March 2014. Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio...